Clinical Trial Update: Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on dose-dense chemotherapy (ddEC-ddP) for neoadjuvant treatment of HER2-negative breast cancer, spanning Phase 2 and Phase 3, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: HER2-negative Breast Cancer, Neoadjuvant Chemotherapy | Phase 2, Phase 3 | Status: RECRUITING